FAQs

While neither hair loss nor weight gain have been reported as side effects of Mirapex ER in clinical trials, some patients who received the drug or its older immediate-release formulation after their approval have experienced these effects. Also, weight loss has been reported in clinical trials of these formulations in…

In the trials that supported Mirapex ER’s approval, early Parkinson’s patients showed a significant reduction in motor impairment as early as 18 weeks, or about four months, after starting treatment. In advanced Parkinson’s patients, significant improvements in motor symptoms and daily off periods were seen as early as…

Some people on Mirapex ER may experience severe sleepiness or suddenly fall asleep during daily activities. Until patients know how the therapy affects them, those starting Mirapex ER are recommended to avoid driving or other activities that may be potentially dangerous if the individual becomes somnolent. If patients do experience…

Animal data has suggested that Mirapex ER may cause fetal harm. However, there are no clinical data on the medication’s effects on pregnant patients, so it is unclear whether the therapy is safe in this population. Patients should talk with their doctor about any plans for being pregnant while on…

The U.S. Food and Drug Administration approved Mirapex ER in February 2010 for lessening signs and symptoms of early-stage Parkinson’s disease. That indication was then expanded to also include people with advanced disease. An earlier, immediate-release formulation of the therapy had been approved in 1997, but has since been…

While hair loss and weight gain have not been reported as side effects of Inbrija in clinical trials, patients may experience weight gain due to the therapy’s potential to cause impulse control disorders, including compulsive eating. Hair and weight loss are reported as potential side effects of the therapy on…

In the trials that supported Inbrija’s approval, patients experienced reductions in motor symptoms during off periods as early as 10 minutes post-dosing, with significant effects being observed after 30 minutes. Still, as each person can respond differently to a medication, patients are advised to talk with their healthcare team on…

Some people on levodopa-based treatments have reported extreme somnolence or falling asleep during daily activities. Thus, until patients know how the medication affects them, those starting starting Inbrija should avoid driving, operating machinery, or other activities that may result in harm if they suddenly fall asleep.

Clinical trials of Inbrija have not included pregnant patients, so the therapy’s safety in such conditions remains largely unknown. However, animal data has suggested that it may cause fetal harm. Patients should talk with their doctor about any plans for being pregnant while on Inbrija.

The U.S. Food and Drug Administration (FDA) approved Inbrija in December 2018 as an add-on treatment for off periods in Parkinson’s disease patients on levodopa and carbidopa. That decision made Inbrija the first inhaled levodopa therapy in the U.S. for Parkinson’s off episodes.